WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

A Comprehensive Review of Asthma: Unraveling Etiological Factors, Pathophysiological Mechanisms, and Preventive Approaches

Ditij Dhameliya[1], Samarth Parmar[2], Meet Sonani[3], Kush Avaiya[4], Parth Sonani[5], Udhdhav Jani[6], Rudra Jani[7], Raj Vala[8]

[1,2,3,4,5,6,7,8] Student at Gyanmanjari Pharmacy College, Bhavnagar-364004, Gujarat, India

A B S T R A C T

Eosinophilic inflammation and airway remodeling in the bronchial airways are the hallmarks of asthma, a chronic lung disease. Even in quiescent states of the disease, Th2 cells are still functional, and IL-13 a crucial effector cytokine increases mucus production, epithelium damage, and eosinophilia in addition to stimulating airway fibrosis. Local reactions of smooth muscle, fibroblasts, and epithelium increase inflammation by releasing chemokines, cytokines, and proteases. Mucosal inflammation and airway remodeling have an impact on the pathophysiology and management of asthma. It is still unknown how precisely particular inflammatory cells and their mediators relate to airway hyperresponsiveness and clinical symptoms. To fully comprehend the regulation and connection between fibrotic alterations and inflammation, more research is required. Asthma stems from abnormalities in the developed airway components, such as the smooth muscle, vasculature, and epithelium.

INTRODUCTION

The term "asthma," which means "short of breath" in Greek, describes any patient who is unable to breathe. Henry Hyde Salter's "On Asthma and its Treatment," published in the late 19th century, improved the definition of the term asthma by defining it as "Paroxysmal dyspnoea of a peculiar character with intervals of healthy respiration between attacks." The cellular appearance of asthmatic sputum and the airways involved in asthma and bronchitis were accurately shown in Salter's work. He also mentioned using black coffee, a beverage with a high theobromine content, to relieve asthmatic spasms. Due to his own experience with asthma, Dr. Salter gained valuable insight into the condition. Physicians began to accept the idea that asthma was a separate illness with unique etiology, clinical implications, and treatment needs by the late 19th century. Asthma was originally mentioned by Sir William Osler, the founder of modern medicine in the West, in his 1892 textbook Principles and Practice of Medicine. Bronchial muscle spasms, bronchial mucous membrane enlargement, inflammation of smaller bronchioles, and a host of conditions that might trigger paroxysms—including environment, fear, food, and cold infection—are the hallmarks of asthma.

Asthma as an element of respiratory disorders

The nominalist approach to defining diseases, particularly asthma, has been the most detailed discourse on the subject between 1959 and 1996. Guy Scadding, the founding Professor of Medicine at the Institute of Diseases of the Chest in London, now the National Heart and Lung Institute, advocates for this definition. He defines a disease as the sum of abnormal phenomena displayed by a group of living organisms in association with a specific common characteristic by which they differ from the norm for their species in such a way as to place them at a biological disadvantage.

Asthma can be defined better than a syndrome, except in young children or underdeveloped or remote where objective measurements might not be available. In the early 1960s, Scadding suggested that asthma should refer to an abnormality of function as a disease characterized by wide variations over short periods in resistance to flow in intrapulmonary airways. This approach was also adopted by the American Thoracic Society.

Asthma is synonymous with variable airflow limitation, but the airway disease can include other components, such as eosinophilic, allergens, steroid reduction, neutrophilic, viral infections, bacteria, cigarette smoking, occupational pollutants, chemical sensitizers, unknown, both neutrophilic and eosinophilic, or neither (paucigranulocytic). Different cellular types of airway inflammation is common in chronic airway disease in general.

Asthma cannot be defined by a cause because there are many or by pathology. After all, the commonly described pathologic features are not specific to asthma. Thus, different cellular types of airway inflammation are common in chronic airway disease in general. Other features seen in asthma include increased smooth muscle mass in the airway walls in children with cystic fibrosis and non-cystic fibrosis bronchiectasis, subepithelial thickening in allergic rhinitis without asthma and in asymptomatic patients with AHR, and epithelial denudation seen in endobronchial biopsies may be an artifact and does not always correlate with the severity of symptoms, AHR, or airflow obstruction.

Nominalist definitions also apply to emphysema and bronchiectasis, which are based on pathological structural changes. It also applies to 'bronchitis', which can be referred to as 'inflammation in the airways'. The airway inflammation can be objectively identified by inflammatory markers in sputum, bronchial wash, bronchoalveolar lavage, or bronchial biopsy. Refined methods of quantitative sputum cell counts are the most clinically applicable and discriminative at present.

The use of the term 'eosinophilic bronchitis' in connection with asthma is not new, as it can occur without its presence and can also occur with rhinitis or COPD without asthma. Proof that bronchitis, hyperresponsiveness, and symptoms can occur independently of each other is also provided by mathematical models. By using a nominalist approach to definitions, individual patients might have combinations of asthma, COPD, emphysema, bronchiectasis, or bronchitis of different types.

Causes of asthma

Chronic asthma is a respiratory disease marked by inflammation, mucus production that is elevated, and airway constriction. Although the precise reason is still unknown, a number of factors influence its development

1. Genetic Factors:

- Family History: Asthma tends to run in families, suggesting a genetic predisposition.
- Inherited Susceptibility: Certain genes may influence an individual's likelihood of developing asthma.

2. Environmental Triggers:

Allergens: Symptoms of asthma can be brought on by exposure to allergens such as mold, dust mites, pollen, and animal dander.

- Irritants: Tobacco smoke, chemical pollutants, and cold air can exacerbate asthma.
- Infections: Respiratory infections (e.g., colds, flu) can worsen asthma symptoms.
- Weather Changes: Extreme temperatures, humidity fluctuations, and windy conditions may impact airway function.
- Exercise: Physical activity can trigger asthma attacks in some individuals.
- Emotional Stress: Intense emotions may lead to asthma symptoms.
- Gastroesophageal Reflux Disease (GERD): Acid reflux can worsen asthma.
- Medications: Certain drugs like aspirin, beta-blockers, and NSAIDs may provoke asthma attacks.
- Food Allergies: Some foods (e.g., eggs, cow milk, peanuts, wheat, fish, shellfish) can act as triggers.

3. Other Risk Factors:

Obesity: People who are overweight have a higher chance of getting asthma.

- Premature Birth and Low Birth Weight: These factors may increase susceptibility.
- Maternal Factors: Poor maternal nutrition, lack of breastfeeding, and young motherhood play a role.
- Smoking: One major risk factor is being exposed to secondhand smoke or actively smoking.

4. Complications:

- Deterioration of Lung Function: Uncontrolled asthma can lead to progressive lung damage.
- Airway Inflammation: Chronic inflammation affects daily activities.
- Hospitalization: Severe asthma attacks may require hospitalization.

5. Prevention and Management:

- Avoid Triggers: Identify and avoid asthma triggers (e.g., allergens, exercise-induced triggers).
- Medication: Follow prescribed medications (e.g., inhalers, tablets).
- Proper Inhaler Use: Learn correct inhaler techniques.
- Regular Monitoring: Pay close attention to your breathing, and if your symptoms get worse, get help right once.

Pathophysiology of asthma

The main characteristic of asthma, notwithstanding its complexity, is a persistent inflammation of the airways. The following outlines the main participants in the pathophysiology of asthma:

Inflammation of the Airways:

The lining of healthy airways is smooth and permits unobstructed airflow. When someone has asthma, immune cells such as mast cells and eosinophils infiltrate the airways, causing inflammation and swelling. The airways become narrower and more susceptible to stimuli as a result of this inflammation.

Enhanced Production of Mucus:

Excess mucus produced by inflamed airways further plugs the airways and prevents airflow

Asthma constriction:

Asthma sufferers' airways overreact and constrict (tighten) in response to triggers because immune cells release substances like histamine. Asthma symptoms are caused by a severe reduction in airflow caused by bronchoconstriction.

Remodeling an airway:

Airway remodeling is the term for long-term alterations in the airways caused by chronic inflammation in asthma. This involves harm to the lining, an increase in smooth muscle mass, and thickening of the airway walls. These modifications may permanently decrease airflow and exacerbate asthmatic symptoms.

Triggers:

Asthma patients may experience bronchoconstriction and an inflammatory reaction due to a variety of causes. These triggers fall into the following general categories: Allergens: People with allergic asthma may experience an immunological reaction when they inhale allergens such as pollen, dust mites, or pet dander. Irritants: Cold air, smoke, harsh chemicals, and air pollution can all irritate the airways and narrow them down. Other triggers: For some people, exercise, respiratory infections, and even emotional stress can aggravate asthma symptoms.

The Two Stages of an Allergic Reaction:

Early Phase: Bronchoconstriction and airway narrowing occur instantly as a result of mast cells releasing inflammatory mediators such as histamine in response to a trigger. Within minutes of exposure, wheezing, coughing, and dyspnea result from this.

Late Phase: A subsequent inflammatory response involving extra immune cells may occur a few hours after the first stimulus. These protracted symptoms and continued airway narrowing may be caused by this late-phase inflammation.

Prevention of asthma

Since asthma is a chronic illness, it can be controlled with a variety of preventative techniques. People should recognize their triggers, manage indoor allergens, and stay away from outdoor allergens in order to prevent asthma. Dust mites can be decreased by regular cleaning, dust mite coverings, and humidity management. On days when the pollen count is high, stay indoors and keep windows closed to avoid outdoor allergens. Asthma is greatly increased by secondhand smoke exposure, so abstain from smoking and stay away from those who smoke. Lowering respiratory infections in young children can also assist in lowering the chance of developing asthma. Frequently cleaning your hands and avoiding close contact with ill people can help lower your risk of infection. Asthma symptoms can also be controlled by nursing, maintaining an active lifestyle, and maintaining a healthy weight. Doctor-prescribed controller drugs can be helpful.

Conclusion

Chronic lung diseases, such as asthma and COPD, have nominalist definitions and are influenced by various factors, leading to heterogeneity in disease severity. Asthma refers to variations in resistance to flow in intrapulmonary airways, while COPD is a different physiologic abnormality. Asthma can be present without evidence of bronchitis but often occurs with eosinophilic or noneosinophilic bronchitis, COPD, or sometimes with bronchiectasis or emphysema. Accurate diagnosis requires measurements, which can help identify current asthma. However, other components of the disease, such as bronchitis presence, type, and severity, also need consideration. This allows for personalized treatment and avoidance strategies.

The prevalence of certain forms of allergic disease is not yet determined, but potential factors include environmental pollution enhancing allergic responses and a failure to realign the immune system due to inappropriate or insufficient microbial challenge during childhood. It is crucial to identify key variables influencing allergic disease development and expression and clarify the roles of environmental pollution and other factors. This understanding will enable a more accurate evaluation of risks to human health.

REFERENCE

1. Sakula A. Henry Hyde Salter (1823-71): A biographical sketch. Thorax. 1985;40:887– 888. [PMC free article] [PubMed] [Google Scholar]

2. Vyas H, Krishnaswamy G. Paul Ehrlich's "Mastzellen"--from aniline dyes to DNA chip arrays: A historical review of developments in mast cell research. Methods Mol Biol. 2006;315:3–11. [PubMed] [Google Scholar]

3. McEwen BJ. Eosinophils: A review. Vet Res Commun. 1992;16:11–44. [PubMed [Google Scholar]

4. Osler W. The Principles and Practice of Medicine. 1st ed. NY: D. Appleton and Company; 1892. pp. 497–501. [Google Scholar]

5. Pearce N. The use of beta-agonists and the risk of death and near death from asthma. J Clin Epidemiol. 2009;62:582–587. [PubMed] [Google Scholar]

6. Holgate ST. Pathogenesis of asthma. Clin Exp Allergy. 2008;38:872–897. [PubMed] [Google Scholar]

7. Ovary Z. From prausnitz-kustner to passive cutaneous anaphylaxis and beyond. Chem Immunol. 1990;49:90–120. [PubMed] [Google Scholar]

8. Ishizaka K, Ishizaka T. Mechanisms of regaining hypersensitivity and IgE antibody response. Immunol Rev. 1978;41:109–148. [PubMed] [Google Scholar]

9. Austen KF. Reaction mechanisms in the release of mediators of immediate hypersensitivity from human lung tissue. Fed Proc. 1974;33:2256–2262. [PubMed] [Google Scholar]

10. Durham SR, Carroll M, Walsh GM, Kay AB. Leukocyte activation in allergen-induced late-phase asthmatic reactions. N Engl J Med. 1984;311:1398–1402. [PubMed] [Google Scholar]

11. Holgate ST. Reflections on the mechanism(s) of action of sodium cromoglycate (Intal) and the role of mast cells in asthma. Respir Med. 1989;83(Suppl A):25–31. [PubMed] [Google Scholar]

12. Turner-Warwick M. Corticosteroid aerosols: The future? Postgrad Med J. 1974;50(suppl 4):80–84. [PubMed] [Google Scholar]

13) Ciba Foundation Guest Symposium. Terminology, definitions, and classification of chronic pulmonary emphysema and related conditions. Thorax 1959; 14:286–99.

14) Scadding JG. Principles of definition in medicine with special reference to chronic bronchitis and emphysema. Lancet 1959; i:323–5.

15) Orie NGM, Sluiter HJ Bronchitis: an International Symposium; 27–29 April 1960, University of Groningen, the Netherlands. Assen, the Netherlands: Royal Van Gorcum, 1961.

16) American Thoracic Society. Definitions and classifications of chronic bronchitis, asthma, and pulmonary emphysema and related conditions. Am Rev Respir Dis 1962; 85:762–8.

17) Orie NGM, Sluiter HJ Bronchitis II: Second International Symposium. Assen, the Netherlands: Royal Van Gorcum, 1964; 398–9.

18) Ciba Foundation Study Group No. 38. Identification of asthma. Churchill Livingstone, Edinburgh, 1971.

19) Hargreave FE, Parameswaran K. Asthma, COPD, and bronchitis are just components of airway disease. Eur Respir J 2006; 28:264–7.

20) D'silva L, Cook RJ, Allen CJ, Hargreave FE, Parameswaran K. Changing pattern of sputum cell counts during successive exacerbations of airway disease. Respir Med 2007; 101:2217–20.

21) Ryan G, Latimer KM, Dolovich J, Hargreave FE. Bronchial responsiveness to histamine: relationship to diurnal variation of peak flow rate, improvement after bronchodilator and airway caliber. Thorax 1982; 37:423–9.

22) A¨ delroth E, Morris MM, Hargreave FE, O'Byrne PM. Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. N Engl J Med 1986; 315:480–4.

23) Thomson NC, Roberts R, Bandouvakis J, Newball H, Hargreave FE. Comparison of bronchial responses to prostaglandin F2a and methacholine. J Allergy Clin Immunol 1981; 68:392–8.

24) Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004; 56:515–48.

25) Cockcroft DW, Hargreave FE, O'Byrne PM, Boulet LP. Understanding allergic asthma from allergen inhalation tests. Can Respir J 2007; 14:414–8.

26) Lemie`re C, Chaboillez S, Malo JL, Cartier A. Changes in sputum cell counts after exposure to occupational agents: what do they mean? J Allergy Clin Immunol 2001; 107:1063–8.

27) Lemanske RF Jr, Dick EC, Swenson CA, Virtis RF, Busse WW.Rhinovirus upper respiratory infection increases airway hyperreactivity and late asthmatic reactions. J Clin Invest 1989;